Helix Biopharma Corp. HBP.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 54.87% | 48.27% | 25.76% | 82.06% | 19.45% |
| Total Depreciation and Amortization | -100.00% | -50.00% | -51.72% | -68.18% | -27.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -135.78% | -93.71% | 143.44% | -98.67% | 296.12% |
| Change in Net Operating Assets | -272.70% | -22.26% | -144.60% | -76.27% | -85.82% |
| Cash from Operations | 35.28% | 50.28% | -39.64% | 13.53% | -17.19% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,573.00% | -- | -- | -- | -94.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,705.68% | -100.42% | -- | -100.09% | -94.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 327.49% | -127.07% | 149.94% | -274.64% | -307.29% |